Insider Transactions in Q3 2024 at Cytom X Therapeutics, Inc. (CTMX)
Insider Transaction List (Q3 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 20
2024
|
Christopher Ogden Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,984
-1.8%
|
$1,984
$1.23 P/Share
|
|
Aug 20
2024
|
Christopher Ogden Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,875
+5.88%
|
-
|
|
Aug 20
2024
|
Lloyd A Rowland General Counsel |
SELL
Open market or private sale
|
Direct |
4,181
-3.1%
|
$4,181
$1.23 P/Share
|
|
Aug 20
2024
|
Lloyd A Rowland General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
11,250
+7.69%
|
-
|
|
Aug 20
2024
|
Marcia Belvin SVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
4,181
-2.33%
|
$4,181
$1.23 P/Share
|
|
Aug 20
2024
|
Marcia Belvin SVP, Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,250
+5.89%
|
-
|
|
Aug 20
2024
|
Jeffrey B Landau Chief Business Officer |
SELL
Open market or private sale
|
Direct |
4,181
-3.39%
|
$4,181
$1.23 P/Share
|
|
Aug 20
2024
|
Jeffrey B Landau Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,250
+8.37%
|
-
|
|
Aug 20
2024
|
Sean A. Mc Carthy CEO |
SELL
Open market or private sale
|
Direct |
13,898
-2.07%
|
$13,898
$1.23 P/Share
|
|
Aug 20
2024
|
Sean A. Mc Carthy CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
37,500
+5.29%
|
-
|